Drug Maker Alexion Agrees To Settle SEC Foreign Bribery Probe For ‘Less Than $25M’
BOSTON — Biopharmaceutical company Alexion Pharmaceuticals Inc. on May 6 told shareholders that on March 30, it reached an agreement in principle with the U.S. Securities and Exchange Commission to settle...To view the full article, register now.
Already a subscriber? Click here to view full article